# Tavalisse

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/tavalisse
Canonical HTML page: https://getyourbrief.com/entity/tavalisse

## Timeline

- **2026-03-03**: Q4 Earnings Release — Both companies scheduled to report full-year 2025 financial results.
- **2025-09-15**: ARCT-032 Phase 1b — Arcturus releases positive interim data for Cystic Fibrosis candidate.
- **2023-11-28**: Kostaive Approval — Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.

## Recent coverage (3 stories, network-wide)

### Rigel and Cumberland Q4 Results Signal Commercial Maturity in Specialty Pharma
2026-03-05 12:08:35 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Rigel Pharmaceuticals and Cumberland Pharmaceuticals reported Q4 results that emphasize commercial execution and a shift toward sustainable profitability. Both companies are leveraging core hospital and oncology assets to navigate a market that increasingly rewards revenue-generating biotechs over speculative R&D.
Full story: https://getbiobrief.com/story/rigel-cumberland-q4-earnings-analysis-2026

### Specialty Pharma Resilience: Rigel and Cumberland Q4 Earnings Analysis
2026-03-05 12:08:31 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Rigel and Cumberland Pharmaceuticals reported Q4 results highlighting steady commercial growth in specialty oncology and hospital-based therapies. Both companies are prioritizing portfolio optimization and pipeline advancement to navigate a competitive biotech landscape.
Full story: https://gethealthbrief.com/story/rigel-cumberland-q4-earnings-specialty-pharma-analysis

### Biotech Earnings Preview: Arcturus and Rigel Set for Pivotal Q4 Reports
2026-03-02 22:53:40 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
Full story: https://gethealthbrief.com/story/arcturus-rigel-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.